You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國中藥(00570.HK)附屬與國藥工程及武漢宏利簽訂醇提取車間建設項目-淨化工程施工協議

格隆匯9月1日丨中國中藥(00570.HK)發佈公告,公司附屬公司同濟堂製藥於2025年9月1日簽訂下列協議:(1)與國藥工程及武漢宏利簽訂醇提取車間建設項目-淨化工程施工協議:國藥工程與武漢宏利爲同濟堂製藥醇提取車間及其配套機房、罐區提供建築裝飾裝修工程、給排水工程、暖通工程、電氣工程、工藝管道工程、熱力工程、自控工程、不鏽鋼器具、鋼平臺、設備工程等施工。

(2)與國藥工程簽訂醇提取車間建設項目-污水預處理配套設備設施採購項目協議:國藥工程爲同濟堂製藥醇提取車間建設項目提供污水預處理配套設備設施建設,包括勘察、設計、工藝設備採購安裝及配套設施施工等。

該等協議項下擬進行的關連交易乃同濟堂製藥醇提取車間建設項目的重要組成部分,而醇提取車間建設項目是支撐同濟堂製藥核心產品生產、提升產能和質量的關鍵工程。透過與國藥工程訂立該等協議,將能充分發揮國藥集團內部協同優勢,節約項目成本、提升整體效率。國藥工程具有建築工程總承包二級、建築機電安裝專業承包一級、建築裝飾裝修工程專業承包二級、環保工程專業承包二級,以及工程監理專業乙級等工程施工及管理資質。在招標過程中,同濟堂製藥考慮了本公告前述所提及的因素以及國藥工程所具備的資質,決定接受國藥工程的投標書及委託其提供前述服務。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account